C Henry1, A Quadir, N J Hawkins, E Jary, E Llamosas, D Kumar, B Daniels, R L Ward, C E Ford. 1. Adult Cancer Program, Level 2, Metastasis Research Group, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, UNSW, NSW, 2052, Australia, c.henry@student.unsw.edu.au.
Abstract
PURPOSE: Wnt signalling has been implicated in breast cancer, and in particular aberrant β-catenin-independent Wnt signalling has been associated with breast cancer metastasis and Tamoxifen resistance. Despite Wnt pathway involvement in many human cancers, attempts to target the pathway therapeutically have been disappointing. The recent discovery that the receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a novel Wnt receptor provides a potential new therapeutic and diagnostic target. METHODS: To clarify the role of ROR2 in breast cancer, we investigated its expression via ROR2 immunohistochemistry in a clinical cohort of breast cancer patients, and via in vitro studies incorporating both overexpression and knock-down of ROR2. RESULTS: ROR2 was expressed in the majority of breast cancer patients (87%), including those classed as triple negative. Breast cancer patients expressing ROR2 had a significantly shorter overall survival than those lacking ROR2 expression (P < 0.05). Overexpression of ROR2 in the mammary epithelial cell line, MCF10A, increased both β-catenin-dependent and β-catenin-independent targets and decreased cell adhesion. Knock-down of ROR2 in the breast cancer cell lines, MDA-MB-453 and HCC1143, decreased both β-catenin-dependent and β-catenin-independent targets and increased cell adhesion. Treatment of ROR2-expressing breast cancer cells with the novel berberine derivative, NAX53, significantly inhibited cell proliferation and migration. CONCLUSIONS: This is the first study to report the expression of ROR2 in breast cancer. Breast cancer patients expressing ROR2 had a significantly worse prognosis than those lacking ROR2. ROR2 may regulate both β-catenin-dependent and β-catenin-independent Wnt signalling pathways, and represents a potential diagnostic and therapeutic target.
PURPOSE: Wnt signalling has been implicated in breast cancer, and in particular aberrant β-catenin-independent Wnt signalling has been associated with breast cancer metastasis and Tamoxifen resistance. Despite Wnt pathway involvement in many humancancers, attempts to target the pathway therapeutically have been disappointing. The recent discovery that the receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a novel Wnt receptor provides a potential new therapeutic and diagnostic target. METHODS: To clarify the role of ROR2 in breast cancer, we investigated its expression via ROR2 immunohistochemistry in a clinical cohort of breast cancerpatients, and via in vitro studies incorporating both overexpression and knock-down of ROR2. RESULTS:ROR2 was expressed in the majority of breast cancerpatients (87%), including those classed as triple negative. Breast cancerpatients expressing ROR2 had a significantly shorter overall survival than those lacking ROR2 expression (P < 0.05). Overexpression of ROR2 in the mammary epithelial cell line, MCF10A, increased both β-catenin-dependent and β-catenin-independent targets and decreased cell adhesion. Knock-down of ROR2 in the breast cancer cell lines, MDA-MB-453 and HCC1143, decreased both β-catenin-dependent and β-catenin-independent targets and increased cell adhesion. Treatment of ROR2-expressing breast cancer cells with the novel berberine derivative, NAX53, significantly inhibited cell proliferation and migration. CONCLUSIONS: This is the first study to report the expression of ROR2 in breast cancer. Breast cancerpatients expressing ROR2 had a significantly worse prognosis than those lacking ROR2. ROR2 may regulate both β-catenin-dependent and β-catenin-independent Wnt signalling pathways, and represents a potential diagnostic and therapeutic target.
Authors: Kristel J M Janssen; A Rogier T Donders; Frank E Harrell; Yvonne Vergouwe; Qingxia Chen; Diederick E Grobbee; Karel G M Moons Journal: J Clin Epidemiol Date: 2010-03-24 Impact factor: 6.437
Authors: A H S Lee; S E Pinder; R D Macmillan; M Mitchell; I O Ellis; C W Elston; R W Blamey Journal: Eur J Cancer Date: 2005-12-27 Impact factor: 9.162
Authors: Angel Arnaout-Alkarain; Harriette J Kahn; Steven A Narod; Ping A Sun; Alexander N Marks Journal: Mod Pathol Date: 2007-01-05 Impact factor: 7.842
Authors: Neal R Rasmussen; Tricia M Wright; Samira A Brooks; Kathryn E Hacker; Zufan Debebe; Adam B Sendor; Matthew P Walker; Michael Ben Major; Jennifer Green; Geoffrey M Wahl; W Kimryn Rathmell Journal: J Biol Chem Date: 2013-07-26 Impact factor: 5.157
Authors: Lucy R Webster; Shu-Fen Lee; Clare Ringland; Adrienne L Morey; Andrew M Hanby; Graeme Morgan; Karen Byth; Patricia A Mote; Pamela J Provan; Ian O Ellis; Andrew R Green; Gillian Lamoury; Peter Ravdin; Christine L Clarke; Robyn L Ward; Rosemary L Balleine; Nicholas J Hawkins Journal: Clin Cancer Res Date: 2008-10-15 Impact factor: 12.531
Authors: Yan Ni Loh; Ellen L Hedditch; Laura A Baker; Eve Jary; Robyn L Ward; Caroline E Ford Journal: BMC Cancer Date: 2013-04-02 Impact factor: 4.430
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: Sean S Q Ma; Claire E Henry; Estelle Llamosas; Rupert Higgins; Benjamin Daniels; Luke B Hesson; Nicholas J Hawkins; Robyn L Ward; Caroline E Ford Journal: Virchows Arch Date: 2016-09-08 Impact factor: 4.064
Authors: María Victoria Castro; Gastón Alexis Barbero; Paula Máscolo; María Belén Villanueva; Jérémie Nsengimana; Julia Newton-Bishop; Edith Illescas; María Josefina Quezada; Pablo Lopez-Bergami Journal: J Cell Commun Signal Date: 2022-06-20 Impact factor: 5.782